Compass Pathways plc, a biotechnology company developing evidence-based treatments for mental health, announced that it granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees on May 1, 2026. The awards consisted of options to purchase an aggregate of 125,335 shares and restricted share units covering an aggregate of 59,625 shares for UK employees.
The equity awards were granted at an exercise price of $9.01 per share, the closing price of the company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date. Stock options will vest over a four-year period with 25 percent vesting on the first anniversary of the grant date and the remaining 75 percent vesting in equal monthly installments over the three-year period thereafter, subject to continued employment. Restricted share units and nominal cost options will vest in four equal annual installments, also subject to continued employment.
Compass Pathways is dedicated to accelerating patient access to innovation in mental health, motivated by the need to find better treatments for people with serious mental health conditions not helped by existing therapies. The company is pioneering COMP360, an investigational synthetic psilocybin treatment for treatment-resistant depression. COMP360 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.
The company is headquartered in London with offices in New York and envisions a world where mental health means not just the absence of illness but the ability to thrive. Compass is pursuing phase 3 clinical trials in treatment-resistant depression and a phase 2b/3 trial in post-traumatic stress disorder as it advances its investigational psilocybin treatment toward potential regulatory approval and commercialization.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.financialcontent.com/article/bizwire-2026-5-6-compass-pathways-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4